General Information of Drug (ID: DMTFRLO)

Drug Name
MK-0343 Drug Info
Synonyms GABA-A alpha-2/alpha-3 agonists (anxiolytics), Merck & Co; IDDBCP174406; MRK-409; TPA-023B
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
22609888
CAS Number
CAS 233275-76-8
TTD Drug ID
DMTFRLO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [2]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [3]
PF-4480682 DMWYJHC Neuropathic pain 8E43.0 Discontinued in Phase 2 [4]
CGS-17867A DMMZJY3 Alcohol dependence 6C40.2 Terminated [5]
TBPS DMFC3XP Discovery agent N.A. Investigative [2]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [6]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [7]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [2]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [8]
[3H]CGS8216 DMLP68J Inflammation 1A00-CA43.1 Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flumazenil DMPCG2L Benzodiazepine overdose PC91 Approved [9]
GSK683699 DMTW79H Inflammatory bowel disease DD72 Phase 2 [3]
Adipiplon DM821BS Sleep-wake disorder 7A00-7B2Z Phase 2 [10]
NS-2710 DMMUR6V Anxiety disorder 6B00-6B0Z Phase 2 [11]
AZD6280 DMFAZLU Anxiety disorder 6B00-6B0Z Discontinued in Phase 1 [12]
TBPS DMFC3XP Discovery agent N.A. Investigative [9]
AMENTOFLAVONE DMLRNV2 Discovery agent N.A. Investigative [6]
Ro-15-3505 DM4NW3U Discovery agent N.A. Investigative [7]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [9]
[3H]Ro154513 DMMBWKL Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-2 (GABRA2) TTBMV1G GBRA2_HUMAN Modulator [1]
GABA(A) receptor alpha-3 (GABRA3) TT37EDJ GBRA3_HUMAN Modulator [1]

References

1 Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.J Psychopharmacol.2008 Jan;22(1):24-32.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
3 New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
4 WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
5 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
6 Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
7 The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
8 Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
10 Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
11 GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
12 AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.